381
Participants
Start Date
November 27, 2017
Primary Completion Date
March 1, 2019
Study Completion Date
March 1, 2019
Lumateperone
Lumateperone 42 mg (ITI-007 60 mg tosylate)
Placebo
Placebo
Clinical Site, Buffalo
Clinical Site, Charlotte
Clinical Site, Decatur
Clinical Site, Atlanta
Clinical Site, Orange City
Clinical Site, Miami
Clinical Site, Birmingham
Clinical Site, Joliet
Clinical Site, Chicago
Clinical Site, St Louis
Clinical Site, Shreveport
Clinical Site, The Woodlands
Clinical Site, Sherman Oaks
Clinical Site, Bothell
Clinical Site, Burgas
Clinical Site, Kardzhali
Clinical Site, Lovech
Clinical Site, Plovdiv
Clinical Site, Rousse
Clinical Site, Sofia
Clinical Site, Targovishte
Clinical Site, Tsarev Brod
Clinical Site, Varna
Clinical Site, Veliko Tarnovo
Clinical Site, Barranquilla
Clinical Site, Bello
Clinical Site, Pereira
Clinical Site, Moscow
Clinical Site, Nizhny Novgorod
Clinical Site, Omsk
Clinical Site, Saint Petersburg
Clinical Site, Samara
Clinical Site, Saratov
Clinical Site, Tomsk
Clinical Site, Yekaterinburg
Clinical Site, Belgrade
Clinical Site, Kragujevac
Clinical Site, Novi Sad
Clinical Site, Ivano-Frankivsk
Clinical Site, Kharkiv
Clinical Site, Kherson
Clinical Site, Lviv
Clinical Site, Odesa
Clinical Site, Poltava
Clinical Site, Smila
Clinical Site, Uzhhorod
Clinical Site, Vinnytsia
Lead Sponsor
Intra-Cellular Therapies, Inc.
INDUSTRY